Arcus Biosciences is a clinical-stage biotechnology company with a 28% analyst upside and above-average momentum, but its core pipeline is heavily concentrated in a single drug candidate and a single partnership counterparty, revenue is declining 39% year-over-year, and the company is burning cash at 66% of revenue — meaning thesis viability depends almost entirely on pipeline outcomes the data cannot predict.
Thesis pillars
- Pipeline And Counterparty Concentration↓Deteriorating
- Revenue Decline Cash Burn→Stable
- High Put Call Ratio Market Skepticism↑Improving
- +1 more pillar — see the Why tab for full reasoning
Arcus Biosciences, Inc. (RCUS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.45: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 7.33; Below-average business quality.
Arcus Biosciences is a late clinical-stage biopharmaceutical company with four drugs in Phase 3 trials targeting cancers and inflammatory diseases. Revenue comes from collaboration milestones with Gilead Sciences (which holds exclusive commercialization rights outside the U.S.... Read more
Sell if holding. Engine safety override at $26.45: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 7.33; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 3.7/10, high confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated 2026-07-30Recent Developments — Arcus Biosciences, Inc.
Latest news
- NEWS Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A — benzinga Jul 22, 2026 positive
- NEWS Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The Safety And Efficacy O — benzinga Jul 22, 2026 positive
- NEWS Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%? — benzinga Jul 20, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45 — benzinga Jul 20, 2026 positive
- NEWS Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2 — benzinga Jul 1, 2026 positive
Generated 2026-07-31T00:08:42Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinecasdatifan10-K Item 1: 'We currently own all of the commercial rights to casdatifan ... Our first Phase 3 clinical trial, PEAK-1, is evaluating casdatifan'
- HIGHcounterpartyGilead10-K Item 1A: 'We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of certain of our investigational products.'
- HIGHSupplierWuXi Biologics10-K Item 1: 'WuXi Biologics would be our exclusive manufacturer of zimberelimab drug substance with respect to clinical and commercial supplies'
- HIGHSuppliersingle-source contract manufacturers10-K Item 1: 'we have obtained ... drug product for our investigational products from single-source third-party contract manufacturers'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMCOO Jennifer Jarrett resigned effective March 30, 2026. No disagreement with Company operations, policies, or practices cited. Separation agreement provides advisory services through June 30, 2026 with extended option exercise period. No permanent successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Revenue shrinking — -39.3% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -156.4%. Quality floor flags this regardless of sector context.static
Volatile — 5.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.45: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 7.33; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $24.91. Score 3.7/10, high confidence.
Take-profit target: $32.04 (+21.2% upside). Prior stop was $24.91. Stop-loss: $24.91.
Concentration risk — Pipeline: casdatifan; Concentration risk — Counterparty: Gilead; Quality below floor (2.6 < 4.0).
Arcus Biosciences, Inc. trades at a P/E of N/A (forward -8.7). TrendMatrix value score: 4.7/10. Verdict: Sell.
19 analysts cover RCUS with a consensus score of 4.1/5. Average price target: $37.
What does Arcus Biosciences, Inc. do?Arcus Biosciences is a late clinical-stage biopharmaceutical company with four drugs in Phase 3 trials targeting...
Arcus Biosciences is a late clinical-stage biopharmaceutical company with four drugs in Phase 3 trials targeting cancers and inflammatory diseases. Revenue comes from collaboration milestones with Gilead Sciences (which holds exclusive commercialization rights outside the U.S. for anti-TIGIT, anti-PD-1, and CD73 programs) and Taiho Pharmaceutical. Arcus retains U.S. commercial rights to its lead HIF-2α inhibitor casdatifan, currently in Phase 3 in renal cell carcinoma.